Julio Angel Vázquez-Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julio Angel Vázquez-Martínez has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Paulo C. Rodriguez
Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, USA
22 shared publications - Timothy I. Shaw
Moffitt Cancer Center
22 shared publications - Amirsalar Mansouri
Department of Interdisciplinary Oncology, Louisiana State University (LSU) Health School of Medicine-New Orleans, New Orleans, LA 70112, USA
20 shared publications - Augusto C. Ochoa
Louisiana State University Health Sciences Center 9 New Orleans, LA
20 shared publications - Darwin Chang
H. Lee Moffitt Cancer Center and Research Institute 5 Department of Immunology Tampa, Florida
20 shared publications - Dorota Wyczechowska
Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA
20 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but many patients with large B cell lymphoma (LBCL) experience primary resistance or relapse. To uncover resistance mechanisms, here we examine pre-infusion tumor biopsies and observe that increased immunoregulatory macrophages correlate with poor clinical responses. In murine models, CAR T cell-produced interferon-gamma (IFN-γ) upregulates inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Proteomic profiling reveals that iNOS-expressing macrophages promote apoptosis and cell cycle arrest while downregulating protein synthesis machinery in CAR T cells. Metabolically, CAR T cells exhibit reduced glycolytic intermediates and altered tricarboxylic acid (TCA) cycle activity. Pharmacological inhibition of iNOS enhances CAR T cell treatment efficacy in vivo. Elevated levels of iNOS+CD14+ monocytes in leukaphereses are associated with non-durable responses to CAR T cells. Targeting iNOS in immunoregulatory macrophages, potentially by modulating CAR T-produced IFN-γ, could improve LBCL outcomes.
- 31 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but many patients with large B cell lymphoma (LBCL) experience primary resistance or relapse. To uncover resistance mechanisms, here we examine pre-infusion tumor biopsies and observe that increased immunoregulatory macrophages correlate with poor clinical responses. In murine models, CAR T cell-produced interferon-gamma (IFN-γ) upregulates inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Proteomic profiling reveals that iNOS-expressing macrophages promote apoptosis and cell cycle arrest while downregulating protein synthesis machinery in CAR T cells. Metabolically, CAR T cells exhibit reduced glycolytic intermediates and altered tricarboxylic acid (TCA) cycle activity. Pharmacological inhibition of iNOS enhances CAR T cell treatment efficacy in vivo. Elevated levels of iNOS+CD14+ monocytes in leukaphereses are associated with non-durable responses to CAR T cells. Targeting iNOS in immunoregulatory macrophages, potentially by modulating CAR T-produced IFN-γ, could improve LBCL outcomes.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 receptor modulation reduces apoptosis in CD8+ T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 receptor modulation reduces apoptosis in CD8+ T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 antagonism improves anti-tumor therapeutic vaccine efficacy in an in vivo multi-boost immunization regimen.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 antagonism improves anti-tumor therapeutic vaccine efficacy in an in vivo multi-boost immunization regimen.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between GLPG1205 and DMSO in CD8+ T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between GLPG1205 and DMSO in CD8+ T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between DL175 and DMSO in CD8+ T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between DL175 and DMSO in CD8+ T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
BM-MDSCs express more GPR84 mRNA compared to T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
BM-MDSCs express more GPR84 mRNA compared to T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Validation of CRISPR-Cas9 and Global GPR84 knockout.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Validation of CRISPR-Cas9 and Global GPR84 knockout.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Unsupervised clustering of single-cell RNA sequencing.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Unsupervised clustering of single-cell RNA sequencing.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Human GPR84 protein expression level correlate with T cell activation.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Human GPR84 protein expression level correlate with T cell activation.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 modulation regulates T cell cytokine and chemokine secretion.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 modulation regulates T cell cytokine and chemokine secretion.